Leah Kuntz

Prescription Digital Therapeutics: Transforming Health Care Delivery

BPL-003: Positive Phase 2b Open-Label Extension Study Data

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

Positive Phase 3 Results: CTx-1301 for the Treatment of Pediatric ADHD

New Post-Hoc Analysis: Ingrezza 40 mg Leads to Clinically Meaningful Improvements in Tardive Dyskinesia Symptoms

How to Approach Conversations With Adult Patients Who Might Have ADHD: New Tools and Insights

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

FDA Accepts NDA for CTx-1301 for Treatment of ADHD

Asynchronous ADHD Assessment: New Tools for Better Evaluation

Women Are Diagnosed With ADHD 5 Years Later Than Men

Early Dose Management and Up-Titration of Esketamine: ECNP Poster Data

New ECNP Poster Data on Adjunctive Lumateperone for Major Depressive Disorder

Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases

6 Helpful Pearls From the International Guidelines for Algorithmic Treatment of Schizophrenia

Presenting Our October Theme: Lifestyle Psychiatry

Progress Update: LPCN 1154 for the Treatment of Postpartum Depression

XPro1595 in Early Alzheimer Disease With Inflammation: Phase 2 MINDFuL Trial Results Submitted for Publication

Insights on Seltorexant as Adjunctive Treatment for Major Depressive Disorder: A Conversation With Andrew Cutler, MD

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.